OXvax Ltd. is a spin out company from the University of Oxford focused on the development of an advanced next generation dendritic cell vaccine platform for the treatment of solid tumour cancers. The Company’s technology is based on intellectual property from the Fairchild laboratory at the Sir William Dunn School of Pathology and exploits induced pluripotent stem cells (iPSC) as a novel source of CD141+ dendritic cells (DC), a novel proprietary subset whose unique properties make them attractive candidates for cancer immunotherapy.